SciEPublish

The Emerging Role of FBXL19 in the Prediction and Pathogenesis of Inflammatory Lung Diseases

Review Open Access

The Emerging Role of FBXL19 in the Prediction and Pathogenesis of Inflammatory Lung Diseases

Author Information
Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH 43210, USA
*
Authors to whom correspondence should be addressed.

Received: 16 September 2026 Revised: 08 October 2026 Accepted: 03 November 2026 Published: 19 November 2026

Creative Commons

© 2026 The authors. This is an open access article under the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Views:19
Downloads:12
J. Respir. Biol. Transl. Med. 2026, 3(4), 10012; DOI: 10.70322/jrbtm.2026.10012
ABSTRACT: Inflammatory lung diseases can be caused either by direct pulmonary insults via inhaled pathogens, such as bacteria or virus, or by indirect insults secondary to systemic inflammation, such as sepsis. The pathogenesis of inflammatory lung diseases has been extensively investigated. Recent studies focusing on protein ubiquitination provide mechanistic insights into the regulation of inflammatory responses in lung epithelial and endothelial cells. F-box and leucine-rich repeat protein 19 (FBXL19) is a substrate-recognition component of the SKP1-Cullin-1-F-box (SCF) E3 ubiquitin ligase complex. Previous studies have demonstrated that FBXL19 plays an important role in regulating pulmonary inflammation by targeting multiple inflammatory signaling proteins, including interleukin 33 receptor (IL-33R), CREB-Binding Protein (CBP), and Nuclear Factor-κB subunit p65 (NF-κB p65). Furthermore, FBXL19 overexpression attenuates lung inflammation and injury in experimental models of LPS exposure, bacterial infection, and sepsis. FBXL19 exhibits anti-inflammatory property and regulates cytoskeletal organization by targeting multiple substrates, including IL-33R (ST2L/IL1RL1), CBP, FOXM1, NF-κB p65, and Rho GTPases. In this review, we outline recent advances in FBXL19 research, highlighting its critical role in regulating inflammatory responses within the lungs. This review also highlights current knowledge gaps and future research directions, including the potential therapeutic applications of FBXL19 in inflammatory lung diseases, which require further preclinical and clinical validation.
Keywords: Ubiquitination; Ubiquitin E3 ligase; Lung inflammation; ISGylation; Signal transduction
TOP